MX377532B - Sales y formas sólidas de un antibiótico de monobactam. - Google Patents

Sales y formas sólidas de un antibiótico de monobactam.

Info

Publication number
MX377532B
MX377532B MX2018003592A MX2018003592A MX377532B MX 377532 B MX377532 B MX 377532B MX 2018003592 A MX2018003592 A MX 2018003592A MX 2018003592 A MX2018003592 A MX 2018003592A MX 377532 B MX377532 B MX 377532B
Authority
MX
Mexico
Prior art keywords
salts
solid forms
monobactam antibiotic
oxo
amino
Prior art date
Application number
MX2018003592A
Other languages
English (en)
Other versions
MX2018003592A (es
Inventor
Andreas Fisch
Anthony Casarez
Bernd Ulrich Riebesehl
Eric Aubin
Folkert Reck
Heinz Ernst Moser
Marc Schoenhentz
Michael Mutz
Mika Lindvall
Robert Lowell Simmons
Vijay Sethuraman
Zaixing Li
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2018003592A publication Critical patent/MX2018003592A/es
Publication of MX377532B publication Critical patent/MX377532B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención proporciona nuevas formas sólidas, sales y polimorfos del ácido 1- (((Z) - (1- (2-aminotiazol-4-il) -2-oxo-2 - (((3S, 4R) -2- ácido oxo-4 - ((2-oxooxazolidin-3-il) metil) -1-sulfoazetidin-3-il) amino) etiliden) amino) oxi) ciclopropanocarboxílico (al que se hace referencia en este documento como Compuesto X), composiciones farmacéuticas que los contienen, y procesos para su fabricación y uso en terapia.
MX2018003592A 2015-09-23 2016-09-20 Sales y formas sólidas de un antibiótico de monobactam. MX377532B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562222430P 2015-09-23 2015-09-23
PCT/CN2016/099482 WO2017050218A1 (en) 2015-09-23 2016-09-20 Salts and solid forms of monobactam antibiotic

Publications (2)

Publication Number Publication Date
MX2018003592A MX2018003592A (es) 2018-06-18
MX377532B true MX377532B (es) 2025-03-10

Family

ID=58385723

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003592A MX377532B (es) 2015-09-23 2016-09-20 Sales y formas sólidas de un antibiótico de monobactam.

Country Status (26)

Country Link
US (1) US10919887B2 (es)
EP (1) EP3353175B1 (es)
JP (1) JP6837480B2 (es)
KR (1) KR102749337B1 (es)
CN (1) CN108137573B (es)
AU (1) AU2016327264B2 (es)
CA (1) CA2999794C (es)
CL (2) CL2018000745A1 (es)
CY (1) CY1123509T1 (es)
DK (1) DK3353175T3 (es)
EA (2) EA202092620A1 (es)
ES (1) ES2817537T3 (es)
HR (1) HRP20201423T1 (es)
HU (1) HUE050849T2 (es)
IL (1) IL258254B (es)
LT (1) LT3353175T (es)
MA (1) MA42946B1 (es)
MX (1) MX377532B (es)
PH (1) PH12018500653B1 (es)
PL (1) PL3353175T3 (es)
PT (1) PT3353175T (es)
RS (1) RS60805B1 (es)
RU (1) RU2754180C2 (es)
SI (1) SI3353175T1 (es)
SM (1) SMT202000480T1 (es)
WO (1) WO2017050218A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2912656T3 (es) * 2017-08-02 2022-05-26 Novartis Ag Proceso para preparar ácido 1-(((Z)-(1-(2-aminotiazol-4-il)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-il)metil)-1-sulfoacetidin-3-il)amino)etiliden)amino)oxi)ciclopropano carboxílico
JP7120516B2 (ja) * 2017-08-16 2022-08-17 エルジー・ケム・リミテッド Zif系粉末を含む白色顔料、高分子樹脂フィルムおよび白色顔料を使用して媒質の色を変更する方法
US20200360349A1 (en) * 2017-11-10 2020-11-19 Novartis Ag Administration of monobactam for the treatment of urinary tract infection
EP3747883A4 (en) * 2018-01-29 2020-12-16 Medshine Discovery Inc. MONOCYCLIC B-LACTAM COMPOUND FOR TREATING BACTERIAL INFECTION
EP3901150B1 (en) * 2018-12-18 2025-12-03 Shenzhen Optimum Biological Technology Co., Ltd Monocyclic beta-lactam compound for use in the treatment of pneumonia
CN114787158B (zh) * 2019-11-22 2023-10-24 苏州二叶制药有限公司 磺酰脲环取代的单环β-内酰胺类抗生素
US12491180B2 (en) 2019-12-19 2025-12-09 Shenzhen Optimum Biological Technology Co., Ltd Application of compound in treating pneumonia
CN113754651B (zh) 2020-06-02 2023-04-18 中国医学科学院医药生物技术研究所 一种β-内酰胺化合物、其用途及其制备方法
US12516048B2 (en) 2020-08-06 2026-01-06 Ningxia Academy Of Agriculture And Forestry Sciences B-lactam compounds, their preparation and use as antibacterial agents
WO2022185241A1 (en) 2021-03-04 2022-09-09 Bp Asset Vi, Inc. Process for manufacturing a monobactam antibiotic
WO2022185240A1 (en) 2021-03-04 2022-09-09 Bp Asset Vi, Inc. Formulation of a monobactam antibiotic
CN115304594B (zh) * 2022-10-12 2023-02-14 苏州二叶制药有限公司 磺酰脲环取代的化合物的盐型及其晶型

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ205240A (en) 1980-02-07 1984-07-31 Squibb & Sons Inc Sulphonamide derivatives,being starting materials for producing beta-lactams
US4775670A (en) 1980-09-29 1988-10-04 E. R. Squibb & Sons, Inc. 2-oxo-1-azetidinesulfonic acid salts
EP0048953B1 (en) 1980-09-29 1988-03-09 E.R. Squibb & Sons, Inc. Beta-lactam antibiotics
WO1982001873A1 (en) 1980-12-05 1982-06-10 Takeda Chemical Industries Ltd 1-sulfo-2-oxoazetidine derivatives and process for their preparation
US4782147A (en) 1980-12-05 1988-11-01 Takeda Chemical Industries, Ltd. 1-sulfo-2-oxoazetidine derivatives and their production
CA1262128A (en) 1981-08-27 1989-10-03 Christian N. Hubschwerlen .beta.-lactams
IL67451A (en) 1981-12-25 1987-10-20 Takeda Chemical Industries Ltd 4-cyano-2-azetidinones and production thereof and process for the preparation of 4-carbamoyl-2-azetidinones using them
AU564150B2 (en) * 1982-04-30 1987-08-06 Takeda Chemical Industries Ltd. 1-sulfo-2-azetidinone derivatives
KR900005112B1 (ko) 1982-05-31 1990-07-19 반유세이야꾸 가부시끼가이샤 2-옥소-1-아제티딘술폰산 유도체의 제조방법
EP0096297B1 (de) 1982-06-03 1988-06-15 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Verfahren zur Herstellung von 1-Sulfo-2-oxoazetidinderivaten
JPS6153282A (ja) 1984-08-22 1986-03-17 Banyu Pharmaceut Co Ltd 単環β−ラクタム誘導体
JPS6153283A (ja) 1984-08-24 1986-03-17 Banyu Pharmaceut Co Ltd 2−オキソ−1−アゼチジンスルホン酸誘導体
US4610824A (en) 1984-10-09 1986-09-09 E. R. Squibb & Sons, Inc. Hydrazide derivatives of monocyclic beta-lactam antibiotics
US5112968A (en) 1989-07-28 1992-05-12 E. R. Squibb & Sons, Inc. Monobactam hydrazide derivatives
US9238657B2 (en) 2008-10-31 2016-01-19 Shionogi & Co., Ltd. Cephalosporin having catechol group
AU2009329169B2 (en) 2008-12-19 2012-06-28 Pfizer Inc. Monocarbams
AU2011336209B2 (en) 2010-11-29 2015-03-19 Pfizer Inc. Monobactams
UY34585A (es) * 2012-01-24 2013-09-02 Aicuris Gmbh & Co Kg Compuestos b-lactámicos sustituidos con amidina, su preparación y uso
CN103044416A (zh) 2012-12-17 2013-04-17 浙江华方药业有限责任公司 一种卡芦莫南钠的合成方法
US20160326157A1 (en) 2014-01-06 2016-11-10 President And Fellows Of Harvard College Monobactams and methods of their synthesis and use
AP2016009374A0 (en) * 2014-03-24 2016-08-31 Novartis Ag Monobactam organic compounds for the treatment of bacterial infections

Also Published As

Publication number Publication date
HK1257271A1 (en) 2019-10-18
CY1123509T1 (el) 2022-03-24
PT3353175T (pt) 2020-09-10
WO2017050218A1 (en) 2017-03-30
JP6837480B2 (ja) 2021-03-03
IL258254A (en) 2018-05-31
EA037569B1 (ru) 2021-04-15
PL3353175T3 (pl) 2021-02-22
RS60805B1 (sr) 2020-10-30
RU2018114480A (ru) 2019-10-23
KR102749337B1 (ko) 2025-01-03
CN108137573B (zh) 2021-06-11
EA202092620A1 (ru) 2021-06-30
MA42946B1 (fr) 2020-10-28
SI3353175T1 (sl) 2020-11-30
CA2999794A1 (en) 2017-03-30
IL258254B (en) 2021-02-28
MX2018003592A (es) 2018-06-18
JP2018528241A (ja) 2018-09-27
MA42946A (fr) 2018-08-01
CL2019003324A1 (es) 2020-04-17
BR112018005805A2 (pt) 2018-10-16
DK3353175T3 (da) 2020-09-14
EP3353175A1 (en) 2018-08-01
US20180273522A1 (en) 2018-09-27
PH12018500653B1 (en) 2022-05-04
US10919887B2 (en) 2021-02-16
RU2754180C2 (ru) 2021-08-30
HUE050849T2 (hu) 2021-01-28
PH12018500653A1 (en) 2018-10-01
AU2016327264B2 (en) 2019-06-27
HRP20201423T1 (hr) 2020-12-11
LT3353175T (lt) 2020-10-12
AU2016327264A1 (en) 2018-05-10
CL2018000745A1 (es) 2018-06-22
EA201890771A1 (ru) 2018-09-28
KR20180054816A (ko) 2018-05-24
CA2999794C (en) 2023-08-15
RU2018114480A3 (es) 2020-06-09
CN108137573A (zh) 2018-06-08
ES2817537T3 (es) 2021-04-07
SMT202000480T1 (it) 2020-11-10
EP3353175A4 (en) 2019-06-26
EP3353175B1 (en) 2020-08-12

Similar Documents

Publication Publication Date Title
MX377532B (es) Sales y formas sólidas de un antibiótico de monobactam.
BR112019004100A2 (pt) compostos de biarila úteis como imunomoduladores
CO2018004124A2 (es) Compuestos heterocíclicos
CL2017002650A1 (es) Compuestos novedosos
BR112017010354B8 (pt) Compostos de triazolopirimidina, seu uso, e composição farmacêutica
CO2017011484A2 (es) Inhibidores de bromodominio
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
ECSP15008851A (es) Compuestos heteroaromáticos como inhibidores de btk
MX364559B (es) Metodos de purificacion de cannabinoides, composiciones y kits de los mismos.
CL2018001569A1 (es) Compuestos heteroaromáticos como inhibidores de btk
CL2016001889A1 (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1.
BR112016023558A2 (pt) compostos úteis como imunomoduladores
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
UY35467A (es) Compuestos orgánicos
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
CL2015001279A1 (es) Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras.
MX2019001011A (es) Compuestos farmaceuticos.
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
CO2019006687A2 (es) Polimorfos
MX2019007336A (es) Polimorfos.
MX2017007377A (es) Compuestos organicos.
CL2016000568A1 (es) Compuestos derivados de 2h-indazol-2-il-n-hidroxi-2-metilsulfonil-2-metil-butanamida sustituidos o sus sales; sus composiciones farmacéuticas que los contiene y su uso para la prevención y/o tratamiento de infecciones bacterianas gram-negativas.
CO2019002523A2 (es) Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
CR20170513A (es) Derivados de pirazol útiles como inhibidores de proteína activadora de 5-li-poxigenasa (flap).

Legal Events

Date Code Title Description
FG Grant or registration